Equities

Jiangsu Hengrui Pharmaceuticals Co Ltd

600276:SHH

Jiangsu Hengrui Pharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)50.19
  • Today's Change-0.270 / -0.54%
  • Shares traded48.85m
  • 1 Year change+6.47%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 20-Nov-24
Select bar for recommendation details.
Recommendations20-Nov-24
Buy10
Outperform10
Hold5
Sell1
Strong Sell0

Share price forecast in CNY

The 14 analysts offering 12 month price targets for Jiangsu Hengrui Pharmaceuticals Co Ltd have a median target of 56.55, with a high estimate of 123.00 and a low estimate of 45.00. The median estimate represents a 12.67% increase from the last price of 50.19.
High145.1%123.00
Med12.7%56.55
Low-10.3%45.00

Dividends in CNY

In 2023, Jiangsu Hengrui Pharmaceuticals Co Ltd reported a dividend of 0.20 CNY, which represents a 25.00% increase over last year. The 15 analysts covering the company expect dividends of 0.22 CNY for the upcoming fiscal year, an increase of 11.50%.
Div growth (TTM)25.00%
More ▼

Earnings history & estimates in CNY

On Oct 24, 2024, Jiangsu Hengrui Pharmaceuticals Co Ltd reported 3rd quarter 2024 earnings of 0.19 per share.
Average growth rate+10.62%
Jiangsu Hengrui Pharmaceuticals Co Ltd reported annual 2023 earnings of 0.68 per share on Apr 17, 2024.
Average growth rate-3.12%
More ▼

Revenue history & estimates in CNY

Jiangsu Hengrui Medicine Co., Ltd. had 3rd quarter 2024 revenues of 6.59bn. This missed the 6.76bn consensus estimate of the 3 analysts following the company. This was 19.96% above the prior year's 3rd quarter results.
Average growth rate+4.03%
Jiangsu Hengrui Medicine Co., Ltd. had revenues for the full year 2023 of 22.82bn. This was 7.26% above the prior year's results.
Average growth rate+0.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.